Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis-Reference-Cited by-同舟云学术

Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

Published:2020-12 Issue: Volume:150 Page:83-89
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ohashi Kadoaki,Ninomiya Kiichiro,Yoshioka Hiroshige,Bessho Akihiro,Shibayama Takuo,Aoe Keisuke,Ishikawa Nobuhisa,Kozuki Toshiyuki,Kawai Haruyuki,Kuyama Shoichi,Miyoshi Seigo,Fujitaka Kazunori,Obata Hideto,Tsubata Yukari,Awaya Yoshikazu,Inoue Masaaki,Inoue Koji,Horita Naokatsu,Yanai Hiroyuki,Hotta Katsuyuki,Kiura Katsuyuki

Funder

Japan Agency for Medical Research and Development

Japanese government

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR;Maemondo;N. Engl. J. Med.,2010

2. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J. Clin. Oncol.,2013

3. Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer;Soria;N. Engl. J. Med.,2018

4. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease;Ohashi;J. Clin. Oncol.,2013

5. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1;Ohashi;Proc Natl Acad Sci U S A,2012

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR‐mutated NSCLC: translational research of phase III IMPACT study;Molecular Oncology;2023-10-28

2. Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present);Pharmaceuticals;2023-04-03

3. PD-1 blockade augments CD8+ T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancer;Lung Cancer;2023-04

4. HER3-targeted therapeutic antibodies and antibody–drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors;Chinese Medical Journal Pulmonary and Critical Care Medicine;2023-03

5. CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer;Cancer Immunology Research;2022-07-08